Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated an Outperform rating on Sutro Biopharma (NASDAQ:STRO) and maintained a $12 price target.
October 23, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst has reiterated an Outperform rating on Sutro Biopharma and maintained a $12 price target.
The reiteration of an Outperform rating by a reputable analyst like David Nierengarten from Wedbush is a positive signal for Sutro Biopharma. The maintained price target of $12 also indicates a positive outlook for the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100